Navigation Links
Bayer HealthCare Awards Veterinary Students $72,500 in Scholarship Funds for Communications Excellence
Date:11/20/2013

SHAWNEE, Kan., Nov. 20, 2013 /PRNewswire/ -- Bayer HealthCare LLC, Animal Health division announces the launch of the 2014 Bayer Excellence in Communication Award. Rolled out to veterinary students at 28 schools across North America, the award is designed to encourage development of effective communication skills among future veterinarians. The program offers eligible students the chance to compete for one $2,500 scholarship at each participating school by demonstrating strong communication skills with a client in a clinical setting. To compete for the national award, school winners must submit a video of their client interview. The national winner will receive an additional $2,500 scholarship. Scholarships totaling $72,500 will be awarded by Bayer.

The Bayer Excellence in Communication Award was created in response to findings from the Bayer Veterinary Care Usage Study that revealed a communication gap between veterinarians and pet owners, especially as it relates to the value placed on regular veterinary care. Effective communication with pet owners is imperative to becoming a successful veterinarian.[1]

"The purpose of the Bayer Excellence in Communication Award is to help develop strong communications skills among veterinarians that will in turn, result in healthier pets," said Cristiano von Simson, DVM, MBA, director of Veterinary Services, Bayer HealthCare Animal Health. "The overwhelmingly positive response to the award last year, our inaugural year that involved seven veterinary schools, led to our expanding to 21 additional schools. We are confident that student submissions will help encourage other veterinary students to sharpen their veterinary communications skills."

Shaping communications skills from the beginning
In 2001, Bayer HealthCare Animal Health partnered with the Institute for Healthcare Communication to develop the Bayer Communication Project. This collaborative partnership led to the development of a communication skills training module offered to colleges of veterinary medicine. Selected faculty from all U.S. veterinary colleges, trained via the Bayer Communication Project "Train the Trainer" development program, have, in turn, incorporated this training into their curriculum.

Participation in the 2014 Bayer Excellence in Communication Award is open to juniors and seniors enrolled at the participating veterinary colleges. Judging and selection of school-level winners is determined by faculty at each respective college. The national winner will be selected by an independent panel of Bayer Communication Project-trained faculty using a standardized score sheet to evaluate each submission. School-level winners will be selected by March 1, 2014, while the national winner will be chosen by May 1, 2014.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of €18.6 million (2012), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.

Contact:
Staci Gouveia, Tel. 913.268.2577
Email: staci.gouveia@bayer.com

Lauren Dorsch, Tel. 913.268.2747
Email: lauren.dorsch@bayer.com

Find more information about Bayer HealthCare Animal Health at www.animalhealth.bayerhealthcare.com
Follow us on Twitter: @Bayer4animalsUS
Follow us on Facebook: http://www.facebook.com/healthcare.bayer 

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

©Bayer and the Bayer Cross are registered trademarks of Bayer.

[1] International Veterinary Communication Institute, "What is the International Veterinary Communication Institute (IVCI)?" http://www.iccvm.com/index.html. Accessed September 4, 2013.


'/>"/>
SOURCE Bayer HealthCare LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
2. Bayer and the Broad Institute Join Forces to Develop Novel Treatment Options in Cancer Therapy
3. Among the Novel Oral Anticoagulants, Bayer/Janssens Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
4. FDA Advisory Committee Unanimously Recommends Approval Of Bayers Riociguat In Two Pulmonary Hypertension Indications
5. Statement: Bayer Mourns Passing of Senator Frank Lautenberg
6. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
7. Bayer Employee Named Rising Star by Healthcare Businesswomens Association
8. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
9. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
10. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
11. U.S. FDA Grants Priority Review to Bayers Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):